Anticipated FDA decision on RP-A501 approval, Jefferies raised price target on RCKT stock, and potential benefits from Trump-era tariffs.
3 reports, 3 independent
Updated Aug 19
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Anticipated FDA decision on RP-A501 approval, Jefferies raised price target on RCKT stock, and potential benefits from Trump-era tariffs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Rocket
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyJefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains ‘Hold’ Rating With significant hedge fund interest and a share price under $10, Rocket Pharmaceuticals, Inc. (NASDAQ:RCK
- Business WireRocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress Prioritizing development of RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM) to
- ZacksRCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure Rocket Pharmaceuticals RCKT announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its i